Pas de connexion internet — affichage de la version enregistrée de la page.

OMEROS CORP

USUSD
← Vers le screener
US:OMERLSE:0KBU

OMEROS CORP (US:OMER) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
omeros.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
SEATTLE, United States
PDG
Gregory A. Demopulos
Employés
175
Actions en circulation
72.39 M au 2026-08-07
Flottant
69.29 M
Capitalisation boursière
1.44 Md USD
Initiés
4.08%
Investisseurs institutionnels
51.42%
Secteur d'activité (SIC)
Pharmaceutical Preparations
FCF
−68.7 M USD
Dette
87.9 M USD
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
Description

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksOMER principaleUSD19.12 +1.97%actions ordinaires
LSE London Stock Exchange0KBU IOBUSD19.32 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.8.35%6.04 M2026-06-30
Ingalls & Snyder LLC5.06%3.66 M2026-06-30
UBS Group AG4.35%3.15 M2026-06-30
Vanguard Capital Managem…4.24%3.07 M2026-06-30
State Street Corporation3.2%2.32 M2026-06-30
DEMOPULOS GREGORY A. M.D…≈3.03%2.19 M2026-02-18
VANGUARD INDEX FUNDS-Van…3%2.17 M2026-06-30
Geode Capital Management…2.64%1.91 M2026-06-30
iShares Trust-iShares Ru…2.55%1.85 M2026-08-31
Stifel Financial Corpora…2.54%1.84 M2026-06-30
Vanguard Portfolio Manag…1.33%962 8282026-06-30
Invesco Exchange-Traded…1.28%929 5852026-08-31
SPDR SERIES TRUST-State…1.21%873 1732026-08-31
VANGUARD INDEX FUNDS-Van…1.15%831 2182026-06-30
Fidelity Salem Street Tr…1.09%788 5622026-07-31
Invesco Ltd.1.04%751 7712026-06-30
Northern Trust Corporati…1%727 3482026-06-30
iShares Trust-iShares Ru…0.58%421 6002026-08-31
Fidelity Concord Street…0.49%357 3712026-07-31
VANGUARD SCOTTSDALE FUND…0.49%352 6792026-05-31
SCHWAB STRATEGIC TRUST-S…0.47%343 8072026-05-31
CABLE THOMAS J (Director…≈0.05%35 0672026-08-20
HANISH ARNOLD C (Directo…≈0.02%12 4002026-08-27
CANCELMO PETER B. (Gener…≈0%2002026-08-31
BORGES DAVID J. (Officer…—02026-09-23